Tarloxotinib bromide is primarily used in the field of cancer research and treatment. It functions as a prodrug that is activated under hypoxic conditions, which are commonly found in solid tumors. Once activated, it releases a potent EGFR (epidermal growth factor receptor) inhibitor, targeting cancer cells specifically in low-oxygen environments. This selective activation helps minimize damage to healthy tissues, making it a promising candidate for treating cancers with hypoxic regions, such as certain types of lung, breast, and pancreatic cancers. Its application is particularly significant in cases where traditional therapies are less effective due to tumor hypoxia. Ongoing clinical trials are exploring its efficacy and safety in various cancer types.